CorMedix Inc. (NASDAQ:CRMD) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET
Company Participants
Daniel Ferry - Investor Relations
Joe Todisco - Chief Executive Officer
Matt David - Executive Vice President and Chief Financial Officer
Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade
Conference Call Participants
Jason Butler - JMP Securities
Rohit Bhasin - Needham & Company
Operator
Hello and welcome to the CorMedix Inc. First Quarter 2022 Earnings Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Daniel Ferry with LifeSci Advisors. Please go ahead.
Daniel Ferry
Good afternoon and welcome to the CorMedix first quarter 2022 earnings conference call. Leading the call today is Joe Todisco, newly appointed Chief Executive Officer of CorMedix and Dr. Matt David, Executive Vice President and CFO. They are joined by Dr. Phoebe Mounts, EVP, General Counsel and Head of Technical Operations and Erin Mistry, SVP and Head of Payer Strategy, Government Affairs and Trade.
Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include, but are not limited to, any of the following: any statements other than statements of historical fact, regarding management’s expectations, beliefs, goals and plans about the company’s prospects, including its clinical development program, manufacturing activities and marketing approval for DefenCath in the U.S. and other product candidates; future financial position; future revenues and projected costs; potential market acceptance of DefenCath, Neutrolin and other product candidates.
More specifically, forward-looking statements include any statements about our clinical development plans and the submission and timing, cost, progress, results, estimates and interpretations thereof; projections as to the company’s future capital raising and spending and cash position; expectations as to the timing and nature of anticipated regulatory actions; possible product licensing, business development or other transactions; any commercial plans and expectations; market projections for our product candidates; and expectations as to manufacturing and product component costs.
Actual results may differ materially from these projections or estimates due to a variety of important factors, including, but not limited to, uncertainties related to clinical development, regulatory approvals and commercialization. These risks are described in greater detail in CorMedix filings with the SEC. The copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix.